Coding variants in human double-strand break DNA repair genes

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 509, Issue 1-2, 2002, Pages 175-200

  Ruttan, Cindy C ^a   Glickman, Barry W ^a  

^a UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Aging; Cancer; DNA repair; Double strand breaks; Human disease; Molecular epidemiology; Single nucleotide polymorphisms (SNPs)

Indexed keywords

DOUBLE STRANDED DNA;

AGING; AMINO ACID SUBSTITUTION; ARTICLE; BRAIN FUNCTION; CANCER RISK; CODON; DISEASE PREDISPOSITION; DNA REPAIR; DNA SEQUENCE; DNA STRAND BREAKAGE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SUBSTITUTION; CHROMOSOME BREAKAGE; CODON; DNA; DNA REPAIR; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION SURVEILLANCE;

EID: 0037202597     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(02)00218-X     Document Type: Article

References (108)

1. Ronen A., Glickman B.W. Human DNA repair genes. Environ. Mol. Mutagen. 37:2001;241-283.
2. Wood R.D., Mitchell M., Sgouros J., Lindahl T. Human DNA repair genes. Science. 291:2001;1284-1289.
3. Jackson S.P. Sensing and repairing DNA double-strand breaks. Carcinogenesis. 23:2002;687-696.
4. Karran P. DNA double strand break repair in mammalian cells. Curr. Opin. Genet. Dev. 10:2000;144-150.
5. Pastink A., Eeken J.C., Lohman P.H. Genomic integrity and the repair of double-strand DNA breaks. Mutat. Res. 480-481:2001;37-50.
6. Jeggo P.A. Identification of genes involved in repair of DNA double-strand breaks in mammalian cells. Radiat. Res. 150:1998;S80-S91.
7. Elliott B., Jasin M. Double-strand breaks and translocations in cancer. Cell Mol. Life Sci. 59:2002;373-385.
8. Ford J.M., Hanawalt P.C. Role of DNA excision repair gene defects in the etiology of cancer. Curr. Top. Microbiol. Immunol. 221:1997;47-70.
9. Mohrenweiser H.W., Jones I.M. Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation. Mutat. Res. 400:1998;15-24.
10. Muller A., Fishel R. Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC). Cancer Invest. 20:2002;102-109.
11. Jiricny J., Nystrom-Lahti M. Mismatch repair defects in cancer. Curr. Opin. Genet. Dev. 10:2000;157-161.
12. Berneburg M., Lehmann A.R. Xeroderma pigmentosum and related disorders: defects in DNA repair and transcription. Adv. Genet. 43:2001;71-102.
13. vanSteeg H., Kraemer K.H. Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer. Mol. Med. Today. 5:1999;86-94.
14. Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet. 22:1999;231-238.
15. McWhir J., Selfridge J., Harrison D.J., Squires S., Melton D.W. Mice with DNA-repair gene (ERCC-1) deficiency have elevated levels of p53, liver abnormalities and die before weening. Nat. Genet. 5:1993;217-224.
16. Yu J.J., Lee K.B., Mu C., Li Q., Abernathy T.V., Bostick-Bruton F., Reed E. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol. 16:2000;555-560.
17. Morino H., Kawarai T., Izumi Y., Kazuta T., Oda M., Komure O., Udaka F., Kameyama M., Nakamura S., Kawakami H. A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease. Ann. Neurol. 47:2000;528-531.
18. Stanford P.M., Halliday G.M., Brooks W.S., Kwok J.B., Storey C.E., Creasey H., Morris J.G., Fulham M.J., Schofield P.R. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain. 123:2000;880-893.
19. Couch F.J., De Shano M.L., Blackwood M.A., Calzone K., Stopfer J., Campeau L., Ganguly A., Rebbeck T., Weber B.L. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N. Engl. J. Med. 336:1997;1409-1415.
20. Malone K.E., Daling J.R., Thompson J.D., O'Brien C.A., Francisco L.V., Ostrander E.A. BRCA1 mutations and breast cancer in the general population - analyses in women before age 35 years and in women before age 45 with first-degree family history. J. Am. Med. Assoc. 279:1998;922-929.
21. Ho G.H., Phang B.H., Ng I.S.L., Law H.Y., Soo K.C., Ng E.H. Novel germline BRCA1 mutations detected in women in Singapore who developed breast carcinoma before the age of 36 years. Cancer. 89:2000;811-816.
22. Li S.S.-L., Tseng H.-M., Yang T.-P., Liu C.-H., Teng S.-J., Huang H.-W., Chen L.-M., Kao H.-W., Chen J.H., Tseng J.-N., Chen A., Hou M.-F., Huang T.-J., Chang H.-T., Mok K.-T., Tsai J.-H. Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan. Hum. Genet. 104:1999;201-204.
23. NCBI SNP Database ( http://www.ncbi.nlm.nih.gov/SNP ).
24. Human Genic Bi-Allelic SEquences (HGBASE) ( http://hgbase.interactiva.de/).
25. Shattuck-Eidens D., Oliphant A., McClure M., McBride C., Gupte J., Rubano T., Pruss D., Tavtigian S.V., Teng D.H.-F., Adey N., Staebell M., Gumpper K., Lundstrom R., Hulick M., Kelly M., Holmen J., Lingenfelter B., Manley S., Fujimura F., Luce M., Ward B., Cannon-Albright L., Steele L., Offit K., Gilewski T., Norton L., Brown K., Schulz C., Hampel H., Schluger A., Giulotto E., Zoli W., Ravaioli A., Nevanlinna H., Pyrhonen S., Rowley P., Scalia J.L., Michaelson R., Scott R.J., Radice R., Pierotti M.A., Garber J.E., Isaacs C., Peshkin B., Lippman M.E., Dosik M.H., Caligo M.A., Greenstein R.M., Pilarski R., Weber B., Burgemeister R., Frank T.S., Skolnick M.H., Thomas S. BRCA1 sequence analysis in women at high risk for susceptibility mutations. J. Am. Med. Assoc. 278:1997;1242-1250.
26. Santarosa M., Viel A., Dolcetti R., Crivellari D., Magri M.D., Pizzichetta M.A., Tibiletti M.G., Gallo A., Tumolo S., Del Tin L., Boiocchi M. Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer. Int. J. Cancer. 78:1998;581-586.
27. Arnold N., Gross E., Schwarz-Boeger U., Pfisterer J., Jonat W., Kiechle M. A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers. Hum. Mutat. 14:1999;333-339.
28. Cortesi L., Turchetti D., Bertoni C., Bellei R., Mangone L., Vinceti M., Federico M., Silingardi V., Ferrari S. Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations. Genes Chromo. Cancer. 27:2000;130-135.
29. Gorski B., Byrski T., Huzarski T., Jakubowska A., Menkiszak J., Gronwald J., Pluzanska A., Bebenek M., Fischer-Maliszewska L., Grzybowska E., Narod S.A., Lubinski J. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am. J. Hum. Genet. 66:2000;1963-1968.
30. Gross E., Arnold N., Pfeifer K., Bandick K., Keichle M. Identification of specific BRCA1 and BRCA2 variants by DHPLC. Hum. Mutat. 16:2000;345-353.
31. Kijima G., Murakami Y., Ohuchi N., Satomi S., Sekiya T. Nonsense mutation at codon 63 of the BRCA1 gene in Japanese breast cancer patients. Jpn. J. Cancer Res. 89:1998;837-841.
32. Andersen T.I., Eiken H.G., Couch F., Kaada G., Skrede M., Johnsen H., Aloysius T.A., Tveit K.M., Tranebjaerg L., Dorum A., Moller P., Weber B.L., Borresen-Dale A.-L. Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening. Hum. Mutat. 11:1998;166-174.
33. Caligo M.A., Ghimenti C., Cipollini G., Ricci S., Brunetti I., Marchetti V., Olsen R., Neuhausen S., Shattuck-Eidens D., Conte P.F., Skolnick M.H., Bevilacqua G. BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. Oncogene. 13:1996;1483-1488.
34. Diez O., Cortes J., Domenech M., Brunet J., Del Rio E., Pericay C., Sanz J., Alonso C., Baiget M. BRCA1 mutation analysis in 83 Spanish breast/ovarian cancer families. Int. J. Cancer. 83:1999;465-469.
35. Gayther S.A., Russell P., Harrington P., Antoniou A.C., Easton D.F., Ponder B.A.J. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am. J. Hum. Genet. 65:1999;1021-1029.
36. Shiri-Sverdlov R., Oefner P., Green L., Baruch R.G., Wagner T., Kruglikova A., Haitchick S., Hofstra R.M.W., Papa M.Z., Mulder I., Rizel S., Sade R.B.B., Dagan E., Abdeen Z., Goldman B., Friedman E. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Hum. Mutat. 16:2000;491-501.
37. Gao Q., Tomlinson G., Das S., Cummings S., Sveen L., Fackenthal J., Schumm P., Olopade O.I. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum. Genet. 107:2000;186-191.
38. Sng J.-H., Chang J., Feroze R., Rahman N., Tan W., Lim S., Lehnert M., van der Pool S., Wong J. The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. Br. J. Cancer. 82:2000;538-542.
39. Durocher F., Shattuck-Eidens D., McClure M., Labrie F., Skolnick M.H., Goldgar D.E., Simard J. Comparison of BRCA1 polymorphisms. Hum. Mol. Genet. 5:1996;835-842.
40. Southey M.C., Tesoriero A.A., Andersen C.R., Jennings K.M., Brown S.M., Dite G.S., Jenkins M.A., Osborne R.H., Maskiell J.A., Porter L., Giles G.G., McCredie M.R.E., Hopper J.L., Venter D.J. BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br. J. Cancer. 79:1999;34-39.
41. Janezic S.A., Ziogas A., Krumroy L.M., Krasner M., Plummer S.J., Cohen P., Gildea M., Barker D., Haile R., Casey G., Anton-Culver H. Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Hum. Mol. Genet. 8:1999;889-897.
42. Katagiri T., Emi M., Ito I., Kobayashi K., Yoshimoto M., Iwase T., Kasumi F., Miki Y., Skolnick M.H., Nakamura Y. Mutations in the BRCA1 gene in Japanese breast cancer patients. Hum. Mutat. 7:1996;334-339.
43. Ozdag H., Tez M., Sayek I., Muslumanoglu M., Tarcan O., Icli F., Ozturk M., Ozcelik T. Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients. Eur. J. Cancer. 36:2000;2076-2082.
44. Dunning A.M., Chiano M., Smith N.R., Dearden J., Gore M., Oakes S., Wilson C., Stratton M., Peto J., Easton D., Clayton D., Ponder B.A. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum. Mol. Genet. 6:1997;285-289.
45. Goode E.L., Dunning A.M., Kuschel B., Healey C.S., Day N.E., Ponder B.A.J., Easton D.F., Pharoah P.P.D. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res. 62:2002;3052-3057.
46. Hadjisavvas A., Adamou A., Phanis C.O.D., Todd C.M., Kitsios P., Kyriacou K., Christodoulou C.G. Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Cypriot family. Oncol. Rep. 9:2002;383-386.
47. Markoff A., Sormbroen H., Bogdanova N., Preisler-Adams S., Ganev V., Dworniczak B., Horst J. Comparison of conformation-sensitive gel electrophoresis and single-strand conformation polymorphism analysis for detection of mutations in the BRCA1 gene using optimized conformation analysis protocols. Eur. J. Hum. Genet. 6:1998;145-150.
48. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., Bell R., Rosenthal J., Hussey C., Tran T., McClure M., Frye C., Hattier T., Phelps R., Haugen-Strano A., Katcher H., Yakumo K., Gholami Z., Shaffer D., Stone S., Bayer S., Wray C., Bogden R., Dayananth P., Ward J., Tonin P., Narod S., Bristow P.K., Norris F.H., Helvering L., Morrison P., Rosteck P., Lai M., Barrett J.C., Lewis C., Neuhausen S., Cannon-Albright L., Goldgar D., Wiseman R., Kamb A., Skolnick M.H. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71.
49. Geisler J.P., Hatterman-Zogg M.A., Rathe J.A., Lallas T.A., Kirby P., Buller R.E. Ovarian cancer BRCA1 mutation detection: protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP). Hum. Mutat. 18:2001;337-344.
50. Whitehead Institute For Biomedical Research (http://www-genome.wi.mit.edu/).
51. Ghaderi A., Talei A., Farjadian S., Mosalaei A., Doroudchi M., Kimura H. Germline BRCA1 mutations in Iranian women with breast cancer. Cancer Lett. 165:2001;87-94.
52. Lancaster J.M., Berchuck A., Futreal P.A., Wiseman R.W. Dideoxy fingerprinting assay for BRCA1 mutation analysis. Mol. Carcin. 17:1997;176-179.
53. JCIB SNP Database ( http://snp.ims.u-tokyo.ac.jp ).
54. Hogervorst F.B.L., Cornelis R.S., Bout M., van Vliet M., Oosterwijk J.C., Olmer R., Bakker B., Klijn J.G.M., Vasen H.F.A., Meijers-Heijboer H., Menko F.H., Cornelisse C.J., den Dunnen J.T., Devilee P., van Ommen G.-J.B. Rapid detection of BRCA1 mutations by the protein truncation test. Nat. Genet. 10:1995;208-212.
55. Barker D.F., Almeida E.R., Casey G., Fain P.R., Liao S.Y., Masunaka I., Noble B., Kurosaki T., Anton-Culver H. BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype. Genet. Epi. 13:1996;595-604.
56. Theodor L., Bar-Sade R., Kruglikova A., Ben-Baruch G., Risel S., Shiri-Sverdlov R., Hirsh Yechezkel G., Modan B., Papa M.Z., Rechavi G., Friedman E. An identical novel mutation in BRCA1 and a common haplotype in familial ovarian cancer in non-Ashkenazi Jews. Br. J. Cancer. 77:1998;1880-1883.
57. Whitehead Institute For Biomedical Research/MIT Center for Genome Research, Affymetrix data reported on NCBI website: http://www.ncbi.nlm.nih.gov/SNP/.
58. Shen D., Wu Y., Subbarao M., Bhat H., Chillar R., Vadgama J.V. Mutation analysis of BRCA1 gene in African-American patients with breast cancer. J. Natl. Med. Assoc. 92:2000;29-35.
59. Matsushima M., Kobayashi K., Emi M., Saito H., Saito J., Suzumori K., Nakamura Y. Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Hum. Mol. Genet. 4:1995;1953-1956.
60. Bandera C.A., Muto M.G., Schorge J.O., Berkowitz R.S., Rubin S.C., Mok S.C. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet. Gynecol. 92:1998;596-600.
61. UCLA-DOE Laboratory for Structural Biology and Molecular Medicine ( http://www.bioinformatics.ucla.edu/).
62. Huusko P., Paakkonen K., Launonen V., Poyhonen M., Blanco G., Kauppila A., Puistola U., Kiviniemi H., Kujala M., Leisti J., Winqvist R. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am. J. Hum. Genet. 62:1998;1544-1548.
63. Hu N., Li G., Li W.J., Wang C., Goldstein A.M., Tang Z.Z., Roth M.J., Dawsey S.M., Huang J., Wang Q.H., Ding T., Giffen C., Taylor P.R., Emmert-Buck M.R. Infrequent mutation in the BRCA2 gene in esophageal squamous cell carcinoma. Clin. Cancer Res. 8:2002;1121-1126.
64. Couch F.J., Farid L.M., De Shano M.L., Tavtigian S.V., Calzone K., Campeau L., Peng Y., Bogden B., Chen Q., Neuhausen S., Shattuck-Eidens D., Godwin A.K., Daly M., Radford D.M., Sedlacek S.D., Rommens J., Simard J., Garber J., Merajver S., Weber B.L. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat. Genet. 13:1996;123-125.
65. Healey C.S., Dunning A.M., Teare M.D., Chase D., Parker L., Burns J., Chang-Claude J., Mannermaa A., Kataja V., Huntsman D.G., Pharoah P.D.P., Luben R.N., Easton D.F., Ponder B.A.J. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat. Genet. 26:2000;362-364.
66. The SNP Consortium (http://snp.cshl.org/).
67. Malone K.E., Daling J.R., Neal C., Suter N.M., O'Brien C.A., Cushing-Haugen K., Jonasdottir T.J., Thompson J.D., Ostrander E.A. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 88:2000;1393-1402.
68. Santarosa M., Dolcetti R., Magri M.D., Crivellari D., Tibiletti M.G., Gallo A., Tumolo S., Puppa L.D., Furlan D., Boiocchi M., Viel A. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy. Int. J. Cancer. 83:1999;5-9.
69. Peelen T., van Vliet M., Bosch A., Bignell G., Vasen H.F.A., Klijn J.G.M., Meijers-Heijboer H., Stratton M., van Ommen G.-J.B., Cornelisse C.J., Devilee P. Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. Br. J. Cancer. 82:2000;151-156.
70. Verhoog L.C., Brekelmans C.T.M., Seynaeve C., Dahmen G., van Geel A.N., Bartels C.C.M., Tilanus-Linthorst M.M.A., Wagner A., Devilee P., Halley D.J.J., van den Ouweland A.M.W., Meijers-Heijboer E.J., Klijn J.G.M. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J. Clin. Oncol. 17:1999;3396-3402.
71. Kuschel B., Auranen A., McBride S., Novik K.L., Antoniou A., Lipscombe J.M., Day N.E., Easton D.F., Ponder B.A.J., Pharoah P.D.P., Dunning A. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum. Mol. Genet. 11:2002;1399-1407.
72. University of Washington Genome Centre (http://www.genome.washington.edu/projects/egpsnps/).
73. Severin D.M., Leong T., Cassidy B., Elsaleh H., Peters L., Venter D., Southey M., McKay M. Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;1323-1331.
74. Environmental Genome Project Database (http://egp.gs.washington.edu/).
75. Sunyaev S., Hanke J., Brett D., Aydin A., Zastrow I., Lathe W., Bork P., Reich J. Individual variation in protein-coding sequences of human genome. Adv. Protein Chem. 54:2000;409-437.
76. O'Driscoll M., Cerosaletti K.M., Girard P.-M., Dai Y., Stumm M., Kysela B., Hirsch B., Gennery A., Palmer S.E., Seidel J., Gatti R.A., Varon R., Oettinger M.A., Neitzel H., Jeggo P.A., Concannon P. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol. Cell. 8:2001;1175-1185.
77. Genaissance Pharmaceuticals Inc. (http://www.genaissance.com/).
78. Fukuda T., Sumiyoshi T., Takahashi M., Kataoka T., Asahara T., Inui H., Watatani M., Yasutomi M., Kamada N., Miyagawa K. Alterations of the double-strand break repair gene MRE11 in cancer. Cancer Res. 61:2001;23-26.
79. Stewart G.S., Maser R.S., Stankovic T., Bressan D.A., Kaplan M.I., Jaspers N.G., Raams A., Byrd P.J., Petrini J.H., Taylor A.M. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell. 99:1999;577-587.
80. Pitts S.A., Kullar H.S., Stankovic T., Stewart G.S., Last J.I.K., Bedenham T., Armstrong S.J., Paine M., Chessa L., Taylor A.M.R., Byrd P.J. hMRE11: genomic structure and a null mutation identified in a transcript protected from nonsense-mediated mRNA decay. Hum. Mol. Genet. 10:2001;1155-1162.
81. Varon R., Reis A., Henze G., von Einsiedel H.G., Sperling K., Seeger K. Mutations in the Nijmegan breakage syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res. 61:2001;3570-3572.
82. Cutler D.J., Zwick M.E., Carrasquillo M.M., Yohn C.T., Tobin K.P., Kashuk C., Mathews D.J., Shah N.A., Eichler E.E., Warrington J.A., Chakravarti A. High-throughput variation detection and genotyping using microarrays. Genome Res. 11:2001;1913-1925.
83. Kato M., Yano K., Matsuo F., Saito H., Katagiri T., Kurumizaka H., Yoshimoto M., Kasumi F., Akiyama F., Sakamoto G., Nagawa H., Nakamura Y., Miki Y. Identification of Rad51 alteration in patients with bilateral breast cancer. J. Hum. Genet. 45:2000;133-137.
84. Bell D.W., Wahrer D.C.R., Kang D.H., MacMahon M.S., FitzGerald M.G., Ishioka C., Isselbacher K.J., Krainer M., Haber D.A. Common nonsense mutations in RAD52. Cancer Res. 59:1999;3883-3888.
85. Ford B.N., Ruttan C.C., Kyle V.L., Brackley M.E., Glickman B.W. Identification of single nucleotide polymorphisms in human DNA repair genes. Carcinogenesis. 21:2000;1977-1981.
86. Matsuda M., Miyagawa K., Takahashi M., Fukuda T., Kataoka T., Asahara T., Inui H., Watatani M., Yasutomi M., Kamada N., Dohi K., Kamiya K. Mutations in the RAD54 recombination gene in primary cancers. Oncogene. 18:1999;3427-3430.
87. Wellcome Trust Sanger Institute (http://www.sanger.ac.uk/).
88. Hiramoto T., Nakanishi T., Sumiyoshi T., Fukuda T., Matsuura S., Tauchi H., Komatsu K., Shibasaki Y., Inui H., Watatani M., Yasutomi M., Sumii K., Kajiyama G., Kamada N., Miyagawa K., Kamiya K. Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. Oncogene. 18:1999;3422-3426.
89. Stanford Human Genome Center (http://www-shgc.stanford.edu/).
90. Abdel-Rahman S.Z., Soliman A.S., Bondy M.L., Omar S., El-Badawy S.A., Khaled H.M., Seifeldin I.A., Levin B. Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt. Cancer Lett. 159:2000;79-86.
91. David-Beabes G.L., London S.J. Genetic polymorphism of XRCC1 and lung cancer risk among African-Americans and Caucasians. Lung Cancer. 34:2001;333-339.
92. Kim S.-U., Park S.K., Yoo K.-Y., Yoon K.-S., Choi J.Y., Seo J.-S., Park W.-Y., Kim J.-H., Noh D.-Y., Ahn S.-H., Choe K.-J., Strickland P.T., Hirvonen A., Kang D. XRCC1 genetic polymorphism and breast cancer risk. Pharmacogenetics. 12:2002;335-338.
93. Lunn R.M., Langlois R.G., Hsieh L.L., Thompson C.L., Bell D.A. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 59:1999;2557-2561.
94. Olshan A.F., Watson M.A., Weissler M.C., Bell D.A. XRCC1 polymorphisms and head and neck cancer. Cancer Lett. 178:2002;181-186.
95. Shen H., Xu Y., Qian Y., Yu R., Qin Y., Zhou L., Wang X., Spitz M.R., Wei Q. Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population. Int. J. Cancer. 15:2000;601-606.
96. Shen M.R., Jones I.M., Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 58:1998;604-608.
97. Sturgis E.M., Castillo E.J., Li L., Zheng R., Eicher S.A., Clayman G.L., Strom S.S., Spitz M.R., Wei Q. Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis. 20:1999;2125-2129.
98. Tuimala J., Szekely G., Gundy S., Hirvonen A., Norppa H. Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis. 23:2002;1003-1008.
99. Winsey S.L., Haldar N.A., Marsh H.P., Bunce M., Marshall S.E., Harris A.L., Wojnarowska F., Welsh K.I. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res. 60:2000;5612-5616.
100. Divine K.K., Gilliland F.D., Crowell R.E., Stidley C.A., Bocklage T.J., Cook D.L., Belinsky S.A. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat. Res. 461:2001;273-278.
101. Duell E., Wiencke J., Cheng T., Varkonyi A., Zuo Z., Ashok T., Mark E., Wain J., Christiani D., Kelsey K. Polymorphisms in the DNA repair gene XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis. 21:2000;965-971.
102. Hu J.J., Smith T.R., Miller M.S., Mohrenweiser H.W., Golden A., Case L.D. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis. 22:2001;917-922.
103. 32P -DNA adducts in a sample of healthy subjects Carcinogenesis. 22:2001;1437-1445.
104. Park J.Y., Lee S.Y., Jeon H.-S., Bae N.C., Chae S.C., Joo S., Kim C.H., Park J.-H., Kam S., Kim I.S., Jung T.H. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epi. Biomark. Prev. 11:2002;23-27.
105. Relton C.L., Daniel C.P., Chase D.S., Burn J., Tawn E.J. Polymorphisms of the DNA repair gene XRCC1 and the frequency of somatic mutations at the glycophorin A locus in newborns. Mutat. Res. 502:2002;61-68.
106. Rafii S., O'Regan P., Xinarianos G., Azmy I., Stephenson T., Reed M., Meuth M., Thacker J., Cox A. A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Hum. Mol. Genet. 11:2002;1433-1438.
107. David-Beabes G.L., Lunn R.M., London S.J. No association between the XPD (Lys751Gln) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk. Cancer Epi. Biomark. Prev. 10:2001;911-912.
108. Kato M., Iida S., Komatsu H., Ueda R. Lack of ku80 alteration in multiple myeloma. Jpn. J. Cancer Res. 93:2002;359-362.